Company Profiles

driven by the PitchBook Platform

RaNA Therapeutics

Description

Developer of drugs that modulate disease-associated long non-coding RNA (lncRNA), thereby restoring normal expression of individual targeted genes. The platform is based on thousands of gene-associated lncRNA’s that contain binding regions for epigenetic regulatory proteins such as PRC2. Its products are designed to specifically block the binding of the transcriptional repressor complex PRC2 to individual lncRNA regions, thus inducing the expression of the associated target gene.

2010

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$63.8M

Latest Deal Amount

$90M

Total Amount Raised

Description

Developer of drugs that modulate disease-associated long non-coding RNA (lncRNA), thereby restoring normal expression of individual targeted genes. The platform is based on thousands of gene-associated lncRNA’s that contain binding regions for epigenetic regulatory proteins such as PRC2. Its products are designed to specifically block the binding of the transcriptional repressor complex PRC2 to individual lncRNA regions, thus inducing the expression of the associated target gene.

Website:

www.ranarx.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Primary Office

790 Memorial Drive Suite 203 Cambridge, MA 02139United States +1 (617) 945-7361
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore RaNA Therapeutics's full profile, request a free trial.

RaNA Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

RaNA Therapeutics Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

RaNA Therapeutics Investors (12)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Atlas VentureVenture CapitalMinority000 0000000 0000
Brookside CapitalVenture CapitalMinority000 0000000 0000
Leerink PartnersInvestment BankMinority000 0000000 0000
Merck VenturesCorporate Venture CapitalMinority000 0000000 0000
Monsanto Growth VenturesCorporate Venture CapitalMinority000 0000000 0000
Atlas Venture Venture Capital
Brookside Capital Venture Capital
Leerink Partners Investment Bank
Merck Ventures Corporate Venture Capital
Monsanto Growth Ventures Corporate Venture Capital

RaNA Therapeutics Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Ronald Renaud Jr.Chief Executive Officer & Board Member
James Barsoum Ph.DChief Scientific Officer
Balkrishen Bhat Ph.DVice President, Chemistry
Brian FentonVice President, Corporate Development
Daniel LynchExecutive Chairman
Ronald Renaud Jr. Chief Executive Officer & Board Member
James Barsoum Ph.D Chief Scientific Officer
Balkrishen Bhat Ph.D Vice President, Chemistry
Brian Fenton Vice President, Corporate Development
Daniel Lynch Executive Chairman

RaNA Therapeutics Board Members (9)

NameRepresentingRoleSinceContact
Info
Ankit Mahadevia MDAtlas VentureAtlas Advisor000 0000
Brian Gallagher Ph.DSR OnePartner000 0000
Daniel LynchSelfExecutive Chairman000 0000
Iain Dukes Ph.DSelfBoard Member000 0000
Jasper Bos Ph.DMerck VenturesVice President & Head Healthcare000 0000
Ankit Mahadevia MD Atlas Advisor Atlas Venture
Brian Gallagher Ph.D Partner SR One
Daniel Lynch Executive Chairman Self
Iain Dukes Ph.D Board Member Self
Jasper Bos Ph.D Vice President & Head Healthcare Merck Ventures
Request full access to PitchBook